Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.

Literature DB >> 27004212

Visnagin-a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond.

Lei Xi¹.

Abstract

Entities: Chemical Disease Gene

Year: 2016 PMID： 27004212 PMCID： PMC4779788 DOI： 10.3978/j.issn.2305-5839.2015.10.43

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

37 in total

1. Inorganic nitrate therapy improves Doxorubicin-induced cardiomyopathy a new window for an affordable cardiovascular therapy for everyone?

Authors: Andreas Daiber; Tommaso Gori; Thomas Münzel
Journal: J Am Coll Cardiol Date: 2011-05-24 Impact factor: 24.094

2. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin.

Authors: Dirk Lebrecht; Aikaterini Kokkori; Uwe-Peter Ketelsen; Bernhard Setzer; Ulrich A Walker
Journal: J Pathol Date: 2005-12 Impact factor: 7.996

3. Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect.

Authors: Saisudha Koka; Anindita Das; Shu-Guang Zhu; David Durrant; Lei Xi; Rakesh C Kukreja
Journal: J Pharmacol Exp Ther Date: 2010-06-11 Impact factor: 4.030

Review 4. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses.

Authors: R D Olson; P S Mushlin
Journal: FASEB J Date: 1990-10 Impact factor: 5.191

5. Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.

Authors: M R Bristow; J W Mason; M E Billingham; J R Daniels
Journal: Ann Intern Med Date: 1978-02 Impact factor: 25.391

6. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors: Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal: Cancer Date: 2003-06-01 Impact factor: 6.860

7. Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors: Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal: Nat Med Date: 2012-10-28 Impact factor: 53.440

Review 8. Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis.

Authors: Kendall B Wallace
Journal: Cardiovasc Toxicol Date: 2007 Impact factor: 3.231

9. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin.

Authors: Brian B Hasinoff; Daywin Patel; Xing Wu
Journal: Free Radic Biol Med Date: 2003-12-01 Impact factor: 7.376

10. Identification of protein targets underlying dietary nitrate-induced protection against doxorubicin cardiotoxicity.

Authors: Lei Xi; Shu-Guang Zhu; Daniel C Hobbs; Rakesh C Kukreja
Journal: J Cell Mol Med Date: 2011-11 Impact factor: 5.310

4 in total

1. The anticancer activity of visnagin, isolated from Ammi visnaga L., against the human malignant melanoma cell lines, HT 144.

Authors: Fatma Aydoğmuş-Öztürk; Humera Jahan; Neslihan Beyazit; Keriman Günaydın; Muhammad Iqbal Choudhary
Journal: Mol Biol Rep Date: 2019-01-29 Impact factor: 2.316